Global Latisse (Bimatoprost) Market Size, Share, Trends and Forecast 2022-2030


Bimatoprost (CAS 155206-00-1), also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.
Industry Insights

Due to the COVID-19 pandemic, the global Latisse (Bimatoprost) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Latisse (Bimatoprost) market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Latisse (Bimatoprost) landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

Global Latisse (Bimatoprost) (CAS 155206-00-1) key players include Chirogate International, Cayman Pharma, Zhejiang Ausun, Everlight Chemical, and Lianmin Biochemical etc. Global top three players hold a share about 40%. North America is the largest market, with a share about 90%.

This report focuses on Latisse (Bimatoprost) volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Latisse (Bimatoprost) market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe and China, etc.

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Post-covid-19 Outlook

The readers in the section will understand how the Latisse (Bimatoprost) market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Segmental Outlook

Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).

Segment by Purity

Below 99.5%


Segment by Application

Patented Product

General Products

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.

North America

United States











South Korea



China Taiwan




Latin America




Middle East & Africa


Saudi Arabia


Competitive Scenario

In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Cayman Pharma

Tecoland Corporation

TCS Group

Changzhou BOHIV

Zhejiang Ausun

Ansion Pharma

Lianmin Biochemical

Chirogate International

Everlight Chemical



1 Latisse (Bimatoprost) Market Overview
1.1 Product Overview and Scope of Latisse (Bimatoprost)

1.2 Latisse (Bimatoprost) Segment by Purity

1.2.1 Global Latisse (Bimatoprost) Sales Growth Rate Comparison by Purity (2022-2028)

1.2.2 Below 99.5%

1.2.3 Other

1.3 Latisse (Bimatoprost) Segment by Application

1.3.1 Global Latisse (Bimatoprost) Sales Comparison by Application: (2022-2028)

1.3.2 Patented Product

1.3.3 General Products

1.4 Global Latisse (Bimatoprost) Market Size Estimates and Forecasts

1.4.1 Global Latisse (Bimatoprost) Revenue 2017-2028

1.4.2 Global Latisse (Bimatoprost) Sales 2017-2028

1.4.3 Latisse (Bimatoprost) Market Size by Region: 2017 Versus 2021 Versus 2028

2 Latisse (Bimatoprost) Market Competition by Manufacturers

2.1 Global Latisse (Bimatoprost) Sales Market Share by Manufacturers (2017-2022)

2.2 Global Latisse (Bimatoprost) Revenue Market Share by Manufacturers (2017-2022)

2.3 Global Latisse (Bimatoprost) Average Price by Manufacturers (2017-2022)

2.4 Manufacturers Latisse (Bimatoprost) Manufacturing Sites, Area Served, Product Type

2.5 Latisse (Bimatoprost) Market Competitive Situation and Trends

2.5.1 Latisse (Bimatoprost) Market Concentration Rate

2.5.2 The Global Top 5 and Top 10 Largest Latisse (Bimatoprost) Players Market Share by Revenue

2.5.3 Global Latisse (Bimatoprost) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Latisse (Bimatoprost) Retrospective Market Scenario by Region

3.1 Global Latisse (Bimatoprost) Retrospective Market Scenario in Sales by Region: 2017-2022

3.2 Global Latisse (Bimatoprost) Retrospective Market Scenario in Revenue by Region: 2017-2022

3.3 North America Latisse (Bimatoprost) Market Facts & Figures by Country

3.3.1 North America Latisse (Bimatoprost) Sales by Country

3.3.2 North America Latisse (Bimatoprost) Revenue by Country

3.3.3 United States

3.3.4 Canada

3.4 Europe Latisse (Bimatoprost) Market Facts & Figures by Country

3.4.1 Europe Latisse (Bimatoprost) Sales by Country

3.4.2 Europe Latisse (Bimatoprost) Revenue by Country

3.4.3 Germany

3.4.4 France

3.4.5 U.K.

3.4.6 Italy

3.4.7 Russia

3.5 Asia Pacific Latisse (Bimatoprost) Market Facts & Figures by Region

3.5.1 Asia Pacific Latisse (Bimatoprost) Sales by Region

3.5.2 Asia Pacific Latisse (Bimatoprost) Revenue by Region

3.5.3 China

3.5.4 Japan

3.5.5 South Korea

3.5.6 India

3.5.7 Australia

3.5.8 China Taiwan

3.5.9 Indonesia

3.5.10 Thailand

3.5.11 Malaysia

3.6 Latin America Latisse (Bimatoprost) Market Facts & Figures by Country

3.6.1 Latin America Latisse (Bimatoprost) Sales by Country

3.6.2 Latin America Latisse (Bimatoprost) Revenue by Country

3.6.3 Mexico

3.6.4 Brazil

3.6.5 Argentina

3.7 Middle East and Africa Latisse (Bimatoprost) Market Facts & Figures by Country

3.7.1 Middle East and Africa Latisse (Bimatoprost) Sales by Country

3.7.2 Middle East and Africa Latisse (Bimatoprost) Revenue by Country

3.7.3 Turkey

3.7.4 Saudi Arabia

3.7.5 UAE

4 Global Latisse (Bimatoprost) Historic Market Analysis by Purity

4.1 Global Latisse (Bimatoprost) Sales Market Share by Purity (2017-2022)

4.2 Global Latisse (Bimatoprost) Revenue Market Share by Purity (2017-2022)

4.3 Global Latisse (Bimatoprost) Price by Purity (2017-2022)

5 Global Latisse (Bimatoprost) Historic Market Analysis by Application

5.1 Global Latisse (Bimatoprost) Sales Market Share by Application (2017-2022)

5.2 Global Latisse (Bimatoprost) Revenue Market Share by Application (2017-2022)

5.3 Global Latisse (Bimatoprost) Price by Application (2017-2022)

6 Key Companies Profiled

6.1 Cayman Pharma

6.1.1 Cayman Pharma Corporation Information

6.1.2 Cayman Pharma Description and Business Overview

6.1.3 Cayman Pharma Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2017-2022)

6.1.4 Cayman Pharma Latisse (Bimatoprost) Product Portfolio

6.1.5 Cayman Pharma Recent Developments/Updates

6.2 Tecoland Corporation

6.2.1 Tecoland Corporation Corporation Information

6.2.2 Tecoland Corporation Description and Business Overview

6.2.3 Tecoland Corporation Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2017-2022)

6.2.4 Tecoland Corporation Latisse (Bimatoprost) Product Portfolio

6.2.5 Tecoland Corporation Recent Developments/Updates

6.3 TCS Group

6.3.1 TCS Group Corporation Information

6.3.2 TCS Group Description and Business Overview

6.3.3 TCS Group Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2017-2022)

6.3.4 TCS Group Latisse (Bimatoprost) Product Portfolio

6.3.5 TCS Group Recent Developments/Updates

6.4 Changzhou BOHIV

6.4.1 Changzhou BOHIV Corporation Information

6.4.2 Changzhou BOHIV Description and Business Overview

6.4.3 Changzhou BOHIV Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Changzhou BOHIV Latisse (Bimatoprost) Product Portfolio

6.4.5 Changzhou BOHIV Recent Developments/Updates

6.5 Zhejiang Ausun

6.5.1 Zhejiang Ausun Corporation Information

6.5.2 Zhejiang Ausun Description and Business Overview

6.5.3 Zhejiang Ausun Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2017-2022)

6.5.4 Zhejiang Ausun Latisse (Bimatoprost) Product Portfolio

6.5.5 Zhejiang Ausun Recent Developments/Updates

6.6 Ansion Pharma

6.6.1 Ansion Pharma Corporation Information

6.6.2 Ansion Pharma Description and Business Overview

6.6.3 Ansion Pharma Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2017-2022)

6.6.4 Ansion Pharma Latisse (Bimatoprost) Product Portfolio

6.6.5 Ansion Pharma Recent Developments/Updates

6.7 Lianmin Biochemical

6.6.1 Lianmin Biochemical Corporation Information

6.6.2 Lianmin Biochemical Description and Business Overview

6.6.3 Lianmin Biochemical Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Lianmin Biochemical Latisse (Bimatoprost) Product Portfolio

6.7.5 Lianmin Biochemical Recent Developments/Updates

6.8 Chirogate International

6.8.1 Chirogate International Corporation Information

6.8.2 Chirogate International Description and Business Overview

6.8.3 Chirogate International Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2017-2022)

6.8.4 Chirogate International Latisse (Bimatoprost) Product Portfolio

6.8.5 Chirogate International Recent Developments/Updates

6.9 Everlight Chemical

6.9.1 Everlight Chemical Corporation Information

6.9.2 Everlight Chemical Description and Business Overview

6.9.3 Everlight Chemical Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2017-2022)

6.9.4 Everlight Chemical Latisse (Bimatoprost) Product Portfolio

6.9.5 Everlight Chemical Recent Developments/Updates


6.10.1 GENTEC Corporation Information

6.10.2 GENTEC Description and Business Overview

6.10.3 GENTEC Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2017-2022)

6.10.4 GENTEC Latisse (Bimatoprost) Product Portfolio

6.10.5 GENTEC Recent Developments/Updates

7 Latisse (Bimatoprost) Manufacturing Cost Analysis

7.1 Latisse (Bimatoprost) Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Key Suppliers of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.3 Manufacturing Process Analysis of Latisse (Bimatoprost)

7.4 Latisse (Bimatoprost) Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

8.1 Marketing Channel

8.2 Latisse (Bimatoprost) Distributors List

8.3 Latisse (Bimatoprost) Customers

9 Latisse (Bimatoprost) Market Dynamics

9.1 Latisse (Bimatoprost) Industry Trends

9.2 Latisse (Bimatoprost) Market Drivers

9.3 Latisse (Bimatoprost) Market Challenges

9.4 Latisse (Bimatoprost) Market Restraints

10 Global Market Forecast

10.1 Latisse (Bimatoprost) Market Estimates and Projections by Purity

10.1.1 Global Forecasted Sales of Latisse (Bimatoprost) by Purity (2023-2028)

10.1.2 Global Forecasted Revenue of Latisse (Bimatoprost) by Purity (2023-2028)

10.2 Latisse (Bimatoprost) Market Estimates and Projections by Application

10.2.1 Global Forecasted Sales of Latisse (Bimatoprost) by Application (2023-2028)

10.2.2 Global Forecasted Revenue of Latisse (Bimatoprost) by Application (2023-2028)

10.3 Latisse (Bimatoprost) Market Estimates and Projections by Region

10.3.1 Global Forecasted Sales of Latisse (Bimatoprost) by Region (2023-2028)

10.3.2 Global Forecasted Revenue of Latisse (Bimatoprost) by Region (2023-2028)

11 Research Finding and Conclusion

12 Methodology and Data Source

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Author List

12.4 Disclaimer

Choose License Type

Checkout Inquiry Sample